Design Therapeutics, Inc. (DSGN)
DSGN Stock Price Chart
Explore Design Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze DSGN price movements and trends.
DSGN Company Profile
Discover essential business fundamentals and corporate details for Design Therapeutics, Inc. (DSGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Mar 2021
Employees
56.00
Website
https://www.designtx.comCEO
Pratik Shah
Description
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
DSGN Financial Timeline
Browse a chronological timeline of Design Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.34.
Earnings released on 7 Aug 2025
EPS came in at -$0.34 falling short of the estimated -$0.32 by -6.25%.
Earnings released on 7 May 2025
EPS came in at -$0.31 falling short of the estimated -$0.28 by -10.71%.
Earnings released on 10 Mar 2025
EPS came in at -$0.24 surpassing the estimated -$0.28 by +14.29%.
Earnings released on 7 Nov 2024
EPS came in at -$0.23 surpassing the estimated -$0.26 by +11.54%.
Earnings released on 5 Aug 2024
EPS came in at -$0.21 surpassing the estimated -$0.25 by +16.00%.
Earnings released on 8 May 2024
EPS came in at -$0.20 surpassing the estimated -$0.28 by +28.57%.
Earnings released on 19 Mar 2024
EPS came in at -$0.21 surpassing the estimated -$0.32 by +34.38%, while revenue for the quarter reached $838.00K .
Earnings released on 13 Nov 2023
EPS came in at -$0.28 surpassing the estimated -$0.42 by +33.33%.
Earnings released on 14 Aug 2023
EPS came in at -$0.36 surpassing the estimated -$0.41 by +12.20%.
Earnings released on 9 May 2023
EPS came in at -$0.35 surpassing the estimated -$0.37 by +5.41%.
Earnings released on 14 Mar 2023
EPS came in at -$0.31 surpassing the estimated -$0.34 by +8.82%.
Earnings released on 3 Nov 2022
EPS came in at -$0.32 falling short of the estimated -$0.28 by -14.29%.
Earnings released on 8 Aug 2022
EPS came in at -$0.27 falling short of the estimated -$0.25 by -8.00%.
Earnings released on 9 May 2022
EPS came in at -$0.24 falling short of the estimated -$0.22 by -9.09%.
Earnings released on 10 Mar 2022
EPS came in at -$0.20 surpassing the estimated -$0.22 by +9.09%.
Earnings released on 9 Nov 2021
EPS came in at -$0.21 falling short of the estimated -$0.14 by -50.00%.
Earnings released on 9 Aug 2021
EPS came in at -$0.14 surpassing the estimated -$0.18 by +22.22%.
Earnings released on 10 May 2021
EPS came in at -$0.31 falling short of the estimated -$0.07 by -342.86%.
Earnings released on 25 Mar 2021
EPS came in at -$0.09 , while revenue for the quarter reached $20.00K .
Earnings released on 31 Dec 2020
EPS came in at -$0.14 , while revenue for the quarter reached $33.00K .
DSGN Stock Performance
Access detailed DSGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.